Elizabeth Durand Basham, MD
Obstetrics/Gynecology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Offices
- 4
Offices
4 locations · University Healthcare Alliance · 334 clinicians in this group
Looking this up.
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Basham’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A120310 · Current
Licensed to practise in California · since 2012 · expires 2027-12-31 · Creighton University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$26,406
Medicare paid this office $26,406 for 213 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 79 | $8,513 | $80 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 107 | $5,120 | $48 |
| Return visit (30+ min) | 34 | $3,613 | $103 |
| New patient visit (30+ min) | 22 | $2,250 | $102 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 15 | $1,899 | $119 |
See all 7 services
| Short return visit (20+ min) | 79 | $8,513 | $80 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 107 | $5,120 | $48 |
| Return visit (30+ min) | 34 | $3,613 | $103 |
| New patient visit (30+ min) | 22 | $2,250 | $102 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 15 | $1,899 | $119 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 15 | $861 | $57 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 19 | $403 | $15 |
Who their Medicare patients are
213 Original Medicare patients in 2024. Average age 73 · Women 100% · Health risk score 0.74. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 55% · Diabetes 17% · Coronary heart disease 15% · Cancer 13% · Depression 12% · Chronic kidney disease 7% · Atrial fibrillation 7%.
The office billed $102,939, Medicare allowed $34,256 and paid $26,406; for 379 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 213 | 379 | 73 | 0.74 | $102,939 | $26,406 |
| 2023 | 167 | 302 | 73 | 0.84 | $89,262 | $22,950 |
| 2022 | 156 | 300 | 74 | 0.79 | $78,514 | $23,474 |
| 2021 | 142 | 273 | 71 | 0.73 | $86,967 | $22,398 |
| 2020 | 117 | 214 | 71 | 0.80 | $71,884 | $14,238 |
| 2019 | 93 | 178 | 72 | 0.72 | $62,312 | $13,092 |
| 2018 | 129 | 264 | 71 | 0.78 | $89,564 | $17,453 |
| 2017 | 118 | 253 | 72 | 0.84 | $62,819 | $16,162 |
| 2016 | 31 | 63 | 70 | 0.64 | $22,242 | $4,513 |
| 2015 | 115 | 334 | 71 | 0.69 | $74,060 | $22,853 |
| 2014 | 122 | 339 | 69 | 0.71 | $50,800 | $24,232 |
| 2013 | 139 | 347 | 71 | 0.70 | $57,717 | $26,454 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Short return visit (20+ min) | 49 | $5,411 | $80 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 90 | $4,301 | $48 |
| Return visit (30+ min) | 31 | $3,781 | $115 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 18 | $2,274 | $114 |
| New patient visit (30+ min) | 20 | $1,745 | $87 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 19 | $1,062 | $56 |
2022: 6 services
| Short return visit (20+ min) | 50 | $6,762 | $85 |
| Return visit (30+ min) | 38 | $4,659 | $111 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 82 | $3,915 | $48 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 13 | $1,548 | $119 |
| New patient visit (30+ min) | 15 | $1,394 | $93 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 18 | $988 | $55 |
2021: 6 services
| Short return visit (20+ min) | 49 | $5,816 | $87 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 74 | $3,642 | $49 |
| Return visit (30+ min) | 30 | $3,581 | $112 |
| New patient visit (30+ min) | 17 | $1,670 | $98 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 11 | $1,300 | $118 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 15 | $849 | $57 |
2020: 5 services
| Short return visit (20+ min) | 48 | $3,846 | $63 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 63 | $3,079 | $49 |
| Return visit (30+ min) | 19 | $1,832 | $92 |
| New patient visit (30+ min) | 16 | $1,519 | $95 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 13 | $722 | $56 |
2019: 4 services
| Short return visit (20+ min) | 47 | $4,496 | $65 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 43 | $2,041 | $47 |
| Return visit (30+ min) | 11 | $1,153 | $96 |
| New patient visit (30+ min) | 12 | $1,100 | $92 |
2018: 5 services
| Short return visit (20+ min) | 52 | $5,579 | $63 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 66 | $3,008 | $46 |
| New patient visit (30+ min) | 20 | $1,808 | $90 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 11 | $1,601 | $123 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 22 | $1,216 | $55 |
2017: 7 services
| Short return visit (20+ min) | 51 | $4,684 | $64 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 60 | $2,756 | $46 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 32 | $1,778 | $56 |
| New patient visit (45+ min) | 11 | $1,486 | $135 |
| New patient visit (30+ min) | 16 | $1,422 | $89 |
| Return visit (30+ min) | 12 | $1,115 | $86 |
| Short return visit | 13 | $505 | $39 |
2016: 2 services
| Short return visit (20+ min) | 18 | $1,510 | $69 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 12 | $544 | $45 |
2015: 9 services
| Short return visit (20+ min) | 71 | $7,664 | $62 |
| New patient visit (30+ min) | 22 | $2,181 | $99 |
| New patient visit (45+ min) | 15 | $2,121 | $141 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 14 | $2,063 | $121 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 43 | $1,950 | $45 |
| Return visit (30+ min) | 12 | $1,109 | $85 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 17 | $926 | $54 |
| Dxa bone density measurement of hip, pelvis, spine | 14 | $734 | $52 |
| Manual urinalysis test with examination using microscope, non-automated | 12 | $59 | $4 |
2014: 8 services
| Short return visit (20+ min) | 54 | $5,223 | $60 |
| New patient visit (45+ min) | 28 | $3,398 | $121 |
| New patient visit (30+ min) | 29 | $2,488 | $86 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 53 | $2,333 | $44 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 18 | $2,118 | $111 |
| Return visit (30+ min) | 16 | $1,785 | $85 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 30 | $1,606 | $54 |
| Dxa bone density measurement of hip, pelvis, spine | 20 | $1,227 | $61 |
2013: 10 services
| Short return visit (20+ min) | 62 | $5,522 | $65 |
| New patient visit (45+ min) | 24 | $3,486 | $145 |
| New patient visit (30+ min) | 32 | $2,850 | $89 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 44 | $1,950 | $44 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 24 | $1,298 | $54 |
| Return visit (30+ min) | 12 | $1,193 | $99 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 15 | $1,084 | $72 |
| Short return visit | 25 | $1,038 | $36 |
| Dxa bone density measurement of hip, pelvis, spine | 13 | $828 | $64 |
| Manual urinalysis test with examination using microscope, non-automated | 13 | $60 | $4 |
Drugs they prescribed that Part D paid
$41,779
Pharmacies billed $41,779 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 419) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
354 generic and 65 brand-name prescriptions · $41,779 in drug cost · 42 antibiotic prescriptions to 24 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 112 | $9,027 | $81 |
| Estring | 13 | $6,764 | $520 |
| Estradiol (Twice Weekly) | 38 | $3,522 | $93 |
| Yuvafem | 15 | $3,205 | $214 |
| Progesterone | 28 | $1,284 | $46 |
See all 9 drugs
| Estradiol | 112 | $9,027 | $81 |
| Estring | 13 | $6,764 | $520 |
| Estradiol (Twice Weekly) | 38 | $3,522 | $93 |
| Yuvafem | 15 | $3,205 | $214 |
| Progesterone | 28 | $1,284 | $46 |
| Clotrimazole-Betamethasone | 21 | $792 | $38 |
| Valacyclovir | 16 | $354 | $22 |
| Fluconazole | 19 | $250 | $13 |
| Nitrofurantoin Mono-Macro | 20 | $203 | $10 |
Year by year
| 2024 | 419 | 148 | 0% (0) | 16% | $41,779 |
| 2023 | 361 | 139 | 0% (0) | 27% | $43,195 |
| 2022 | 353 | 132 | 0% (0) | 26% | $43,504 |
| 2021 | 237 | 75 | None | 36% | $34,616 |
| 2020 | 193 | 69 | 0% (0) | 24% | $22,654 |
| 2019 | 155 | 53 | 0% (0) | 12% | $11,298 |
| 2018 | 179 | 54 | 0% (0) | 18% | $15,819 |
| 2017 | 175 | 55 | None | 25% | $19,434 |
| 2016 | 68 | 25 | 0% (0) | 40% | $7,652 |
| 2015 | 157 | 50 | 0% (0) | 46% | $18,510 |
| 2014 | 210 | 60 | None | 43% | $16,159 |
| 2013 | 102 | 46 | None | 41% | $6,600 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Estradiol | 77 | $7,679 | $100 |
| Estring | 11 | $6,127 | $557 |
| Premarin | 11 | $5,994 | $545 |
| Estradiol (Twice Weekly) | 34 | $4,054 | $119 |
| Progesterone | 25 | $1,168 | $47 |
| Estradiol (Once Weekly) | 12 | $839 | $70 |
| Clotrimazole-Betamethasone | 23 | $580 | $25 |
| Valacyclovir | 14 | $284 | $20 |
| Nitrofurantoin Mono-Macro | 13 | $146 | $11 |
| Fluconazole | 12 | $135 | $11 |
2022: 10 drugs
| Estradiol | 73 | $8,630 | $118 |
| Premarin | 14 | $7,175 | $512 |
| Estradiol (Once Weekly) | 15 | $1,764 | $118 |
| Progesterone | 13 | $858 | $66 |
| Valacyclovir | 21 | $712 | $34 |
| Clotrimazole-Betamethasone | 21 | $671 | $32 |
| Nitrofurantoin Mono-Macro | 13 | $432 | $33 |
| Medroxyprogesterone Acetate | 12 | $211 | $18 |
| Fluconazole | 17 | $133 | $8 |
| Sumatriptan | 13 | $93 | $7 |
2021: 5 drugs
| Estradiol | 46 | $5,773 | $126 |
| Progesterone | 15 | $1,567 | $104 |
| Estradiol (Once Weekly) | 12 | $1,542 | $129 |
| Estradiol (Twice Weekly) | 11 | $1,431 | $130 |
| Nitrofurantoin Mono-Macro | 11 | $166 | $15 |
2020: 4 drugs
| Estradiol | 30 | $4,836 | $161 |
| Estradiol (Once Weekly) | 11 | $1,359 | $124 |
| Clobetasol Propionate | 12 | $408 | $34 |
| Triamcinolone Acetonide | 13 | $81 | $6 |
2019: 1 drug
| Estradiol | 41 | $4,168 | $102 |
2018: 1 drug
| Estradiol | 52 | $5,299 | $102 |
2017: 2 drugs
| Estrace | 18 | $5,140 | $286 |
| Estradiol | 24 | $2,561 | $107 |
2015: 5 drugs
| Premarin | 12 | $2,956 | $246 |
| Raloxifene | 13 | $2,628 | $202 |
| Estrace | 11 | $2,482 | $226 |
| Estradiol | 18 | $1,516 | $84 |
| Metronidazole | 11 | $342 | $31 |
2014: 6 drugs
| Vivelle-Dot | 32 | $2,924 | $91 |
| Estrace | 16 | $2,634 | $165 |
| Premarin | 14 | $2,598 | $186 |
| Metronidazole | 17 | $384 | $23 |
| Alendronate | 22 | $212 | $10 |
| Medroxyprogesterone Acetate | 12 | $53 | $4 |
2013: 2 drugs
| Estrace | 12 | $1,717 | $143 |
| Femhrt | 11 | $843 | $77 |
Money from drug and device companies
$29 in 2025
| 2025 | 1 | 1 | None | $29 |
| 2024 | 1 | 2 | None | $61 |
| 2020 | 1 | 4 | None | $83 |
| 2019 | 3 | 3 | None | $58 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Hologic Sales and Service | Aptima | $29 | 1 payment
|
See the published payment
| Hologic Sales and Service | Meals · 2025-05-20 | Aptima | $29 |
See earlier years (2024, 2020, 2019)
2024: $61
| Hologic Sales and Service | Acessa Provu System | $61 | 2 payments
|
2020: $83
| AbbVie | Oriahnn | $83 | 4 payments
|
2019: $58
| AbbVie | Orilissa | $24 | 1 payment
|
| Exeltis USA | Slynd | $19 | 1 payment
|
| Allergan | Lo Loestrin Fe | $16 | 1 payment
|
Professional record
- NPI
- 1225290414
- Licence
- CA A120310California A120310: Current · expires 2027-12-31
- Trained
- Creighton University School of Medicine, 2008
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 15151 National Ave, Los Gatos, CA, 95032
- NPI first listed
- 2008-06-28
- NPI last updated
- 2013-01-03
This is when the NPI record was last certified, not a medical board exam.